|Videos|February 2, 2018

Why Are Pseudomonas Infections Getting Harder to Treat?

Author(s)Contagion&reg Editorial Staff

Marin H. Kollef, MD, explains why Pseudomonas infections are getting harder to treat.

Marin H. Kollef, MD, professor of medicine and Virginia E. & Sam J. Golman chair of the Respiratory Intensive Care department of Washington University School of Medicine, explains why Pseudomonas infections are getting harder to treat.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

Why Are Pseudomonas Infections Getting Harder to Treat?

Newsletter

Related Content

Training Healthcare Professionals to Treat High-Consequence Infectious Disease

Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians

Optimism After Open-Label Study as Rising Carbapenem Resistance Shapes Future Treatment Guidance

Emory Healthcare: Melding Critical Care, Infectious Diseases, and Disaster Preparedness Together

Aztreonam-Avibactam Demonstrates Noninferior Cure Rates and Strong Safety Profile Compared With Meropenem/Colistin

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Cases and Conversations: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies

22nd Annual Winter Lung Cancer Conference®

10th Annual School of Gastrointestinal Oncology

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Proactive Adverse Event Management for HER2+ BTC Treatments

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Breaking the 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis Cycle: The Importance of Early Intervention

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

25th Annual International Congress on the Future of Breast Cancer® West

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified